A randomized, open-label, parallel-design, multicenter, Phase III study to compare the safety and efficacy of a fixed dose combination of SULBACTOMAX Vs CEFTRIAXONE in the treatment of hospitalized adult patients with Community-Acquired Pneumonia
Latest Information Update: 18 Sep 2019
At a glance
- Drugs Ceftriaxone/disodium edetate/sulbactam (Primary) ; Ceftriaxone
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Therapeutic Use
- Acronyms LRTI2011KR
- Sponsors Korea Pharma
- 11 Dec 2013 Planned number of patients changed from 124 to 248 as reported by Korean Clinical Trials Register record.
- 10 Jun 2013 New trial record